ESR1 and neoplasm: As demonstrated in numerous in vitro and in vivo studies on the mechanisms of tamoxifen resistance, tumor cells recruit a remarkably wide variety of signaling pathways to achieve the resistant outcome [50,51], including cross talk with EGFR and Her2 [52,53], and enhanced nongenomic signaling accompanied by translocation of ER [54,55].